182 related articles for article (PubMed ID: 27977808)
1. Activated p53 with Histone Deacetylase Inhibitor Enhances L-Fucose-Mediated Drug Delivery through Induction of Fucosyltransferase 8 Expression in Hepatocellular Carcinoma Cells.
Okagawa Y; Takada K; Arihara Y; Kikuchi S; Osuga T; Nakamura H; Kamihara Y; Hayasaka N; Usami M; Murase K; Miyanishi K; Kobune M; Kato J
PLoS One; 2016; 11(12):e0168355. PubMed ID: 27977808
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of autophagy significantly enhances combination therapy with sorafenib and HDAC inhibitors for human hepatoma cells.
Yuan H; Li AJ; Ma SL; Cui LJ; Wu B; Yin L; Wu MC
World J Gastroenterol; 2014 May; 20(17):4953-62. PubMed ID: 24833845
[TBL] [Abstract][Full Text] [Related]
3. Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-κB signaling.
Hsu FT; Liu YC; Chiang IT; Liu RS; Wang HE; Lin WJ; Hwang JJ
Int J Oncol; 2014 Jul; 45(1):177-88. PubMed ID: 24807012
[TBL] [Abstract][Full Text] [Related]
4. α-Fetoprotein promoter-driven Cre/LoxP-switched RNA interference for hepatocellular carcinoma tissue-specific target therapy.
Peng YF; Shi YH; Ding ZB; Zhou J; Qiu SJ; Hui B; Gu CY; Yang H; Liu WR; Fan J
PLoS One; 2013; 8(2):e53072. PubMed ID: 23468839
[TBL] [Abstract][Full Text] [Related]
5. Aspirin minimized the pro-metastasis effect of sorafenib and improved survival by up-regulating HTATIP2 in hepatocellular carcinoma.
Lu L; Sun HC; Zhang W; Chai ZT; Zhu XD; Kong LQ; Wang WQ; Zhang KZ; Zhang YY; Zhang QB; Ao JY; Li JQ; Wang L; Wu WZ; Tang ZY
PLoS One; 2013; 8(5):e65023. PubMed ID: 23741443
[TBL] [Abstract][Full Text] [Related]
6. Arsenic trioxide potentiates the anti-cancer activities of sorafenib against hepatocellular carcinoma by inhibiting Akt activation.
Zhai B; Jiang X; He C; Zhao D; Ma L; Xu L; Jiang H; Sun X
Tumour Biol; 2015 Apr; 36(4):2323-34. PubMed ID: 25416439
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib inhibits proliferation and invasion of human hepatocellular carcinoma cells via up-regulation of p53 and suppressing FoxM1.
Wei JC; Meng FD; Qu K; Wang ZX; Wu QF; Zhang LQ; Pang Q; Liu C
Acta Pharmacol Sin; 2015 Feb; 36(2):241-51. PubMed ID: 25557114
[TBL] [Abstract][Full Text] [Related]
8. In Hepatocellular Carcinoma miR-221 Modulates Sorafenib Resistance through Inhibition of Caspase-3-Mediated Apoptosis.
Fornari F; Pollutri D; Patrizi C; La Bella T; Marinelli S; Casadei Gardini A; Marisi G; Baron Toaldo M; Baglioni M; Salvatore V; Callegari E; Baldassarre M; Galassi M; Giovannini C; Cescon M; Ravaioli M; Negrini M; Bolondi L; Gramantieri L
Clin Cancer Res; 2017 Jul; 23(14):3953-3965. PubMed ID: 28096271
[No Abstract] [Full Text] [Related]
9. Pregnane X receptor mediates sorafenib resistance in advanced hepatocellular carcinoma.
Feng F; Jiang Q; Cao S; Cao Y; Li R; Shen L; Zhu H; Wang T; Sun L; Liang E; Sun H; Chai Y; Li X; Liu G; Yang R; Yang Z; Yang Y; Xin S; Li BA
Biochim Biophys Acta Gen Subj; 2018 Apr; 1862(4):1017-1030. PubMed ID: 29369785
[TBL] [Abstract][Full Text] [Related]
10. Notch3 inhibition enhances sorafenib cytotoxic efficacy by promoting GSK3b phosphorylation and p21 down-regulation in hepatocellular carcinoma.
Giovannini C; Baglioni M; Baron Toaldo M; Ventrucci C; D'Adamo S; Cipone M; Chieco P; Gramantieri L; Bolondi L
Oncotarget; 2013 Oct; 4(10):1618-31. PubMed ID: 24113128
[TBL] [Abstract][Full Text] [Related]
11. 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2.
Ma L; Li G; Zhu H; Dong X; Zhao D; Jiang X; Li J; Qiao H; Ni S; Sun X
Cancer Lett; 2014 Dec; 355(1):96-105. PubMed ID: 25218350
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib enhances the chemotherapeutic efficacy of S-1 against hepatocellular carcinoma through downregulation of transcription factor E2F-1.
Zhai JM; Yin XY; Lai YR; Hou X; Cai JP; Hao XY; Liang LJ; Zhang LJ
Cancer Chemother Pharmacol; 2013 May; 71(5):1255-64. PubMed ID: 23435877
[TBL] [Abstract][Full Text] [Related]
13. Icaritin promotes apoptosis and inhibits proliferation by down-regulating AFP gene expression in hepatocellular carcinoma.
Li H; Liu Y; Jiang W; Xue J; Cheng Y; Wang J; Yang R; Zhang X
BMC Cancer; 2021 Mar; 21(1):318. PubMed ID: 33765973
[TBL] [Abstract][Full Text] [Related]
14. Synergistic interaction between the HDAC inhibitor, MPT0E028, and sorafenib in liver cancer cells in vitro and in vivo.
Chen CH; Chen MC; Wang JC; Tsai AC; Chen CS; Liou JP; Pan SL; Teng CM
Clin Cancer Res; 2014 Mar; 20(5):1274-1287. PubMed ID: 24520095
[TBL] [Abstract][Full Text] [Related]
15. Caveolin-1 upregulates Fut8 expression by activating the Wnt/β-catenin pathway to enhance HCC cell proliferative and invasive ability.
Zhang C; Wu Q; Huang H; Chen X; Huang T; Li W; Zhang J; Liu Y
Cell Biol Int; 2020 Nov; 44(11):2202-2212. PubMed ID: 32710651
[TBL] [Abstract][Full Text] [Related]
16. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X
Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of the prolyl isomerase Pin1 enhances the ability of sorafenib to induce cell death and inhibit tumor growth in hepatocellular carcinoma.
Zheng M; Xu H; Liao XH; Chen CP; Zhang AL; Lu W; Wang L; Yang D; Wang J; Liu H; Zhou XZ; Lu KP
Oncotarget; 2017 May; 8(18):29771-29784. PubMed ID: 28404959
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of the Wnt/β-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma.
Lin HH; Feng WC; Lu LC; Shao YY; Hsu CH; Cheng AL
Cancer Lett; 2016 Oct; 381(1):58-66. PubMed ID: 27431312
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive N-glycan profiles of hepatocellular carcinoma reveal association of fucosylation with tumor progression and regulation of FUT8 by microRNAs.
Cheng L; Gao S; Song X; Dong W; Zhou H; Zhao L; Jia L
Oncotarget; 2016 Sep; 7(38):61199-61214. PubMed ID: 27533464
[TBL] [Abstract][Full Text] [Related]
20. Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancer in vitro and in vivo.
Shao H; Gao C; Tang H; Zhang H; Roberts LR; Hylander BL; Repasky EA; Ma WW; Qiu J; Adjei AA; Dy GK; Yu C
J Hepatol; 2012 Jan; 56(1):176-83. PubMed ID: 21835141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
